Stock Analiz

Fate Therapeutics Inc. FATE

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2013 · data as of November 13, 2026

$1.28Market cap $156M
Open the interactive analysis →

Fate Therapeutics Inc. (FATE) is a healthcare company listed in the US with a market value of about $156M. In the twelve months to September 30, 2026 it had revenue of $5M and net income of -$124M, a net margin of -2619.6%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -27% a year, a 5-year average ROIC of -35%.

About Fate Therapeutics

Fate Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2013. Revenue went from $2M in 2015 to $7M in 2025, growth of about 10.6% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 23% over three years (dilution for shareholders). It spends 1622% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S32.8
P/B1.2
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-68.7%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-51.2%
Revenue growth (5 yrs, per year)-26.7%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-868.7%
ROIC (5-yr avg.)-35.3%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$5M$7M$14M$64M$96M$56M$31M$11M$5M$4M$4M
Net income-$124M-$136M-$186M-$161M-$282M-$212M-$173M-$98M-$67M-$43M-$33M
Free cash flow-$107M-$112M-$124M-$138M-$284M-$214M-$44M-$91M-$41M-$39M-$30M
EPS (diluted)$-1.03$-1.15$-1.64$-1.64$-2.91$-2.24$-2.10$-1.44$-1.19$-1.02$-1.05
Net margin-2619.6%-2051.1%-1366.5%-253.3%-292.6%-379.9%-551.6%-919.0%-1405.0%-1046.1%-760.1%
ROIC—-40.9%-41.1%-31.9%-41.1%-21.6%-21.0%-29.3%-29.6%-34.5%-29.4%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Fate Therapeutics pay a dividend?

Not currently.

Is Fate Therapeutics a good stock to buy?

We do not give buy or sell advice. Fate Therapeutics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.